Skip to content

U-100 unit conversion

Cagrilintide calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

10U-100 units · 0.1 mL

25 mcg per unit · 2500 mcg/mL

How the calculator works, sources and review dates

Cagrilintide math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 5 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-12. source-curated; clinician review pending.

Units chart for listed Cagrilintide sizes

U-100 math for listed Cagrilintide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
5 mg502516.7
10 mg1005033.3

What is Cagrilintide?

The amylin path is different from GLP-1, though combination trials with semaglutide exist. A research C-10 vial is not trial material. The mechanism language is receptor science. It is not a wellness claim.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Human trial

Primary evidence or regulator source

706 adults without diabetes, overweight/obesity

Reported findings. In a 26-week phase 2 randomized trial of 706 adults with overweight or obesity, without diabetes, estimated average weight loss ranged from 6.0% to 10.8% across weekly subcutaneous cagrilintide study groups, versus 3.0% with placebo. These figures assume treatment adherence; doses increased over up to six weeks. These are study results, not dosing advice.

Nonresponse. The abstract does not report the proportion who failed to reach a weight-loss threshold. Treatment discontinuation is not a nonresponse rate.

Harms. Gastrointestinal events affected 41%–63% of cagrilintide participants versus 32% with placebo; administration-site reactions were also frequent. Across all groups, 10% permanently stopped treatment, including 4% because of adverse events.

Limits. No transfer to other routes/formulations/indications; clinician review pending. The primary figures use an analysis assuming adherence. The abstract reports similar reductions when nonadherence was included, without numerical detail. Participants and investigators knew which active treatment was assigned; active versus placebo was masked. These monotherapy findings do not establish combination, other-route or commercial-preparation outcomes.

Preparation: Cagrilintide monotherapy Route: subcutaneous

Read original source ↗

Editorial review 2026-10-12. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not approved. FDA identifies this investigational substance as unapproved.

Compounding

restricted. FDA states this substance cannot be used in compounding under federal law.

Research

investigational. Human obesity trials; investigational evidence is not product approval.

Sport

unknown. Not individually verified; consult the current sport rules. Absence of a listing is not permission.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified formulation-specific human estimate in this source set; no guessed value is supplied.

Listed sizes are 5 mg and 10 mg. Do not copy a combination-trial schedule onto a single research vial. Hold the carton.

Risks and mix-ups already on the record

  • Safety is incomplete; absence of reports does not establish safety.
  • Unknown or incomplete for research formulations; this is not a clearance for use.
  • Unknown or incomplete; do not infer compatibility with medications or other substances.

People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.

Sources

  1. Primary evidence or regulator source · checked 2026-10-09
  2. FDA unapproved GLP-1 safety statement · checked 2026-10-09
  3. ClinicalTrials.gov cagrilintide records · checked 2026-10-09

Questions people ask

Is cagrilintide approved if it has Phase 2 data?

Study evidence is not product approval. FDA records this substance as unapproved and restricted for compounding as of the catalog check date.

Does this page cover CagriSema?

This page does not treat CagriSema as a stack product. Combination trial names belong in a later compare or research card with their own citations.

How many units is a listed Cagrilintide vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.